{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:25Z","timestamp":1790168425230,"version":"4.1.0"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific Research Fund of Tai\u2019an Science and Technology Agency","award":["2019NS180"],"award-info":[{"award-number":["2019NS180"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04330-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:33:59Z","timestamp":1775842439000},"page":"4419-4460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4128-1003","authenticated-orcid":false,"given":"JiaJu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0185-1534","authenticated-orcid":false,"given":"ChunXiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6237-842X","authenticated-orcid":false,"given":"Lidong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6831-2964","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-0920","authenticated-orcid":false,"given":"JiaJu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"17","key":"4330_CR1","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675\u201384.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4330_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2217\/imt-2019-0107","volume":"11","author":"SE Rebuzzi","year":"2019","unstructured":"Rebuzzi SE, Leonetti A, Tiseo M, Facchinetti F. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. Immunotherapy. 2019;11(12):993\u20131003.","journal-title":"Immunotherapy"},{"key":"4330_CR3","doi-asserted-by":"publisher","first-page":"1460480","DOI":"10.3389\/fimmu.2024.1460480","volume":"15","author":"S Jiang","year":"2024","unstructured":"Jiang S, Li X, Li J. Case report: the impact of dissociated response of immunotherapy on the treatment strategy of advanced head and neck cancer. Front Immunol. 2024;15:1460480.","journal-title":"Front Immunol"},{"issue":"11","key":"4330_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543\u201352.","journal-title":"JAMA Oncol"},{"issue":"9","key":"4330_CR5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor. J Thorac Oncol. 2019;14(9):1608\u201318.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"4330_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/cncr.31999","volume":"125","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities. Cancer. 2019;125(8):1341\u20139.","journal-title":"Cancer"},{"issue":"3","key":"4330_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385\u201396.","journal-title":"Ann Oncol"},{"issue":"7","key":"4330_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605\u201311.","journal-title":"Ann Oncol"},{"issue":"1","key":"4330_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","volume":"11","author":"CE Onesti","year":"2019","unstructured":"Onesti CE, Freres P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment. J Thorac Dis. 2019;11(1):35\u20138.","journal-title":"J Thorac Dis"},{"key":"4330_CR10","doi-asserted-by":"publisher","first-page":"678409","DOI":"10.3389\/fphar.2021.678409","volume":"12","author":"P Shen","year":"2021","unstructured":"Shen P, Han L, Ba X, Qin K, Tu S. Hyperprogressive disease in cancers treated with immune checkpoint inhibitors. Front Pharmacol. 2021;12:678409.","journal-title":"Front Pharmacol"},{"key":"4330_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejca.2022.05.042","volume":"172","author":"CG Kim","year":"2022","unstructured":"Kim CG, Hong M, Jeung HC, Lee G, Chung HC, Rha SY, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387\u201399.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4330_CR12","doi-asserted-by":"publisher","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e211136.","journal-title":"JAMA Netw Open"},{"issue":"15","key":"4330_CR13","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"},{"key":"4330_CR14","doi-asserted-by":"publisher","first-page":"1116057","DOI":"10.3389\/fimmu.2023.1116057","volume":"14","author":"K Yan","year":"2023","unstructured":"Yan K, Zhang D, Chen Y, Lu W, Huang M, Cai J, et al. Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Front Immunol. 2023;14:1116057.","journal-title":"Front Immunol"},{"key":"4330_CR15","doi-asserted-by":"publisher","first-page":"918317","DOI":"10.3389\/fphar.2022.918317","volume":"13","author":"D Liu","year":"2022","unstructured":"Liu D, Liu H, Gan J, Zeng S, Zhong F, Zhang B, et al. LY2874455 and abemaciclib reverse FGF3\/4\/19\/CCND1 amplification mediated gefitinib resistance in NSCLC. Front Pharmacol. 2022;13:918317.","journal-title":"Front Pharmacol"},{"key":"4330_CR16","doi-asserted-by":"publisher","first-page":"930096","DOI":"10.3389\/fimmu.2022.930096","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Zhu S, Dong Y, Shao J, Liu B, Shen J. The potential predictive biomarkers for advanced hepatocellular carcinoma treated with anti-angiogenic drugs in combination with PD-1 antibody. Front Immunol. 2022;13:930096.","journal-title":"Front Immunol"},{"issue":"3","key":"4330_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res. 2019;25(3):989\u201399.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4330_CR18","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999\u201310008.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"4330_CR19","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4330_CR20","first-page":"271","volume":"24","author":"S Yao","year":"2021","unstructured":"Yao S, Shi K, Zhang Y. Advances in hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immunotherapy. Zhongguo fei ai za zhi = Chin J Lung Cancer. 2021;24(4):271\u20138.","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"key":"4330_CR21","first-page":"1075641","volume":"2016","author":"S Chubachi","year":"2016","unstructured":"Chubachi S, Yasuda H, Irie H, Fukunaga K, Naoki K, Soejima K, et al. A case of non-small cell lung cancer with possible \u201cDisease Flare\u201d on Nivolumab treatment. Case Rep Oncol Med. 2016;2016:1075641.","journal-title":"Case Rep Oncol Med"},{"issue":"17","key":"4330_CR22","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.ejca.2011.06.012","volume":"47","author":"C Gomez-Roca","year":"2011","unstructured":"Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011;47(17):2512\u20136.","journal-title":"Eur J Cancer"},{"issue":"7","key":"4330_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","volume":"30","author":"CG Kim","year":"2019","unstructured":"Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, et al. Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104\u201313.","journal-title":"Ann Oncol"},{"issue":"12","key":"4330_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","volume":"15","author":"S Champiat","year":"2018","unstructured":"Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15(12):748\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"4330_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36(9):850\u20138.","journal-title":"J Clin Oncol"},{"issue":"6165","key":"4330_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432\u20133.","journal-title":"Science"},{"issue":"3","key":"4330_CR27","doi-asserted-by":"publisher","first-page":"e6970","DOI":"10.1002\/cam4.6970","volume":"13","author":"MJ Kim","year":"2024","unstructured":"Kim MJ, Hong SPD, Park Y, Chae YK. Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: a systematic review and meta-analysis. Cancer Med. 2024;13(3):e6970.","journal-title":"Cancer Med"},{"key":"4330_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-016-0134-0","volume":"4","author":"M Nishino","year":"2016","unstructured":"Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a \u201ccommon language\u201d for the new arena of cancer treatment. J Immunother Cancer. 2016;4:30.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4330_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.currproblcancer.2019.01.008","volume":"43","author":"V Michalarea","year":"2019","unstructured":"Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, et al. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: case series and short literature review. Curr Probl Cancer. 2019;43(5):487\u201394.","journal-title":"Curr Probl Cancer"},{"key":"4330_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","volume":"58","author":"Q Wang","year":"2018","unstructured":"Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125\u201335.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"4330_CR31","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/cancers11111699","volume":"11","author":"JY Kim","year":"2019","unstructured":"Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzid E, Kronbichler A, et al. Hyperprogressive disease during anti-PD-1 (PDCD1) \/ PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers. 2019;11(11):1699.","journal-title":"Cancers"},{"issue":"13","key":"4330_CR32","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4330_CR33","first-page":"306","volume":"27","author":"Y Tong","year":"2024","unstructured":"Tong Y, Long Y, Zhang F, Li J. Advances in pseudoprogression of immune checkpoint inhibitors in non-small cell lung cancer. Zhongguo fei ai za zhi = Chin J Lung Cancer. 2024;27(4):306\u201320.","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"issue":"2","key":"4330_CR34","doi-asserted-by":"publisher","first-page":"200997","DOI":"10.1016\/j.omton.2025.200997","volume":"33","author":"G Kagiya","year":"2025","unstructured":"Kagiya G, Ogawa R, Matsumoto T, Hyodo F, Abe N, Yuzawa A, et al. Real-time imaging reveals radiation-induced intratumor apoptosis via nutrient and oxygen deprivation following vascular damage. Mol Ther Oncol. 2025;33(2):200997.","journal-title":"Mol Ther Oncol"},{"issue":"41","key":"4330_CR35","doi-asserted-by":"publisher","first-page":"eabf6290","DOI":"10.1126\/sciadv.abf6290","volume":"7","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wu M, Cao D, Yang C, Jin J, Wu L, et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv. 2021;7(41):eabf6290.","journal-title":"Sci Adv"},{"issue":"2","key":"4330_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jon.12687","volume":"30","author":"AV Bonm","year":"2020","unstructured":"Bonm AV, Ritterbusch R, Throckmorton P, Graber JJ. Clinical imaging for diagnostic challenges in the management of gliomas: a review. J Neuroimaging. 2020;30(2):139\u201345.","journal-title":"J Neuroimaging"},{"issue":"2","key":"4330_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12254-018-0389-x","volume":"11","author":"L Beer","year":"2018","unstructured":"Beer L, Hochmair M, Prosch H. Pitfalls in the radiological response assessment of immunotherapy. Memo. 2018;11(2):138\u201343.","journal-title":"Memo"},{"issue":"Suppl 4","key":"4330_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(Suppl 4):2\u20139.","journal-title":"Oncologist"},{"issue":"16","key":"4330_CR39","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","volume":"26","author":"L Basler","year":"2020","unstructured":"Basler L, Gabrys HS, Hogan SA, Pavic M, Bogowicz M, Vuong D, et al. Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res. 2020;26(16):4414\u201325.","journal-title":"Clin Cancer Res"},{"key":"4330_CR40","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.critrevonc.2021.103531","volume":"169","author":"MY Chen","year":"2022","unstructured":"Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol. 2022;169:103531.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"4330_CR41","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s00259-021-05610-x","volume":"49","author":"JL Vos","year":"2022","unstructured":"Vos JL, Zuur CL, Smit LA, de Boer JP, Al-Mamgani A, van den Brekel MWM, et al. [(18)F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(6):2010\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4330_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2023.04.014","volume":"188","author":"K Taylor","year":"2023","unstructured":"Taylor K, Zou J, Magalhaes M, Oliva M, Spreafico A, Hansen AR, et al. Circulating tumour DNA kinetics in recurrent\/metastatic head and neck squamous cell cancer patients. Eur J Cancer. 2023;188:29\u201338.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4330_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717\u201321.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4330_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00280-017-3396-4","volume":"80","author":"HK Kim","year":"2017","unstructured":"Kim HK, Heo MH, Lee HS, Sun JM, Lee SH, Ahn JS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol. 2017;80(3):591\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4330_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4330_CR46","first-page":"853","volume":"31","author":"R Bai","year":"2019","unstructured":"Bai R, Li W, Du N, Cui J. Challenges of evaluating immunotherapy efficacy in solid tumors. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 2019;31(6):853\u201361.","journal-title":"Chin J Cancer Res = Chung-kuo yen cheng yen chiu"},{"issue":"3","key":"4330_CR47","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"key":"4330_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112674","author":"M Frelaut","year":"2019","unstructured":"Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under Immunotherapy. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112674.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4330_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jamaoncol.2020.1634","volume":"6","author":"B Kas","year":"2020","unstructured":"Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol. 2020;6(7):1039\u201346.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4330_CR50","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","volume":"26","author":"I Matos","year":"2020","unstructured":"Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria. Clin Cancer Res. 2020;26(8):1846\u201355.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4330_CR51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079\u201390.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"4330_CR52","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of Pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286\u201393.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4330_CR53","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2967\/jnumed.119.237768","volume":"61","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive disease in patients with Non-Small Cell Lung Cancer treated with checkpoint inhibitors: the role of (18)F-FDG PET\/CT. J Nucl Med. 2020;61(6):821\u20136.","journal-title":"J Nucl Med"},{"key":"4330_CR54","doi-asserted-by":"publisher","first-page":"112949","DOI":"10.1016\/j.biopha.2022.112949","volume":"150","author":"LP Zhao","year":"2022","unstructured":"Zhao LP, Hu JH, Hu D, Wang HJ, Huang CG, Luo RH, et al. Hyperprogression, a challenge of PD-1\/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. Biomed Pharmacother. 2022;150:112949.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4330_CR55","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"9","key":"4330_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"Suppl 15","key":"4330_CR57","doi-asserted-by":"publisher","first-page":"S1877","DOI":"10.21037\/jtd.2019.08.88","volume":"11","author":"SCM Lau","year":"2019","unstructured":"Lau SCM, Leighl NB. Hyperprogressive disease with immunotherapy: new directions. J Thorac Dis. 2019;11(Suppl 15):S1877\u201380.","journal-title":"J Thorac Dis"},{"issue":"5","key":"4330_CR58","first-page":"199","volume":"49","author":"M Brzozowa-Zasada","year":"2017","unstructured":"Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, Harabin-Slowinska M, et al. Notch and its oncogenic activity in human malignancies. Eur Surg ACA Acta chirurgica Austriaca. 2017;49(5):199\u2013209.","journal-title":"Eur Surg ACA Acta chirurgica Austriaca"},{"key":"4330_CR59","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","volume":"9","author":"E Gianchecchi","year":"2018","unstructured":"Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol. 2018;9:2374.","journal-title":"Front Immunol"},{"issue":"2","key":"4330_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cancers13020309","volume":"13","author":"S Angelicola","year":"2021","unstructured":"Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, et al. IFN-gamma and CD38 in hyperprogressive cancer development. Cancers. 2021;13(2):309.","journal-title":"Cancers"},{"issue":"2","key":"4330_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","volume":"35","author":"J Dulos","year":"2012","unstructured":"Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169\u201378.","journal-title":"J Immunother"},{"key":"4330_CR62","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of cancer resistance to immunotherapy. Front Oncol. 2020;10:1290.","journal-title":"Front Oncol"},{"issue":"2","key":"4330_CR63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/tox.23887","volume":"39","author":"X Su","year":"2024","unstructured":"Su X, Fu C, Liu F, Bian R, Jing P. T-cell exhaustion prediction algorithm in tumor microenvironment for evaluating prognostic stratification and immunotherapy effect of esophageal cancer. Environ Toxicol. 2024;39(2):592\u2013611.","journal-title":"Environ Toxicol"},{"issue":"11","key":"4330_CR64","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.tcb.2023.03.008","volume":"33","author":"J Liu","year":"2023","unstructured":"Liu J, Cao X. Glucose metabolism of TAMs in tumor chemoresistance and metastasis. Trends Cell Biol. 2023;33(11):967\u201378.","journal-title":"Trends Cell Biol"},{"issue":"11","key":"4330_CR65","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.it.2020.09.007","volume":"41","author":"E Proietti","year":"2020","unstructured":"Proietti E, Rossini S, Grohmann U, Mondanelli G. Polyamines and kynurenines at the intersection of immune modulation. Trends Immunol. 2020;41(11):1037\u201350.","journal-title":"Trends Immunol"},{"issue":"5","key":"4330_CR66","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, Somarribas Patterson LF, Ozturk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182(5):1252-70 e34.","journal-title":"Cell"},{"key":"4330_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"4330_CR68","doi-asserted-by":"publisher","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","volume":"1","author":"T Wu","year":"2016","unstructured":"Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1(6):eaai8593.","journal-title":"Sci Immunol"},{"issue":"37","key":"4330_CR69","doi-asserted-by":"publisher","first-page":"e06827","DOI":"10.1002\/advs.202506827","volume":"12","author":"X Chen","year":"2025","unstructured":"Chen X, Liu D, Jin J, Yao H, Sheng Y, Liu Y, et al. Engineering DNA origami captors for TGFbeta1 sequestration to enhance tumor immune modulation and therapy. Ad Sci. 2025;12(37):e06827.","journal-title":"Ad Sci"},{"issue":"6","key":"4330_CR70","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492\u20139.","journal-title":"Nat Immunol"},{"issue":"1","key":"4330_CR71","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4330_CR72","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","volume":"6","author":"G Shayan","year":"2017","unstructured":"Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017;6(1):e1261779.","journal-title":"Oncoimmunology"},{"issue":"3","key":"4330_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother CII. 2014;63(3):247\u201357.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"8","key":"4330_CR74","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/blood-2010-12-325753","volume":"118","author":"S Solito","year":"2011","unstructured":"Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118(8):2254\u201365.","journal-title":"Blood"},{"issue":"23","key":"4330_CR75","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","volume":"22","author":"M Sade-Feldman","year":"2016","unstructured":"Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in patients with stage IV melanoma treated with Ipilimumab. Clin Cancer Res. 2016;22(23):5661\u201372.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4330_CR76","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/cac2.12605","volume":"44","author":"S Zeng","year":"2024","unstructured":"Zeng S, Hu H, Li Z, Hu Q, Shen R, Li M, et al. Local TSH\/TSHR signaling promotes CD8(+) T cell exhaustion and immune evasion in colorectal carcinoma. Cancer Commun. 2024;44(11):1287\u2013310.","journal-title":"Cancer Commun"},{"issue":"5","key":"4330_CR77","doi-asserted-by":"publisher","first-page":"e85935","DOI":"10.1172\/jci.insight.85935","volume":"1","author":"DE Lowther","year":"2016","unstructured":"Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935.","journal-title":"JCI Insight"},{"issue":"4","key":"4330_CR78","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","volume":"70","author":"A Corthay","year":"2009","unstructured":"Corthay A. How do regulatory T cells work? Scand J Immunol. 2009;70(4):326\u201336.","journal-title":"Scand J Immunol"},{"issue":"2","key":"4330_CR79","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302\u201316.","journal-title":"Immunity"},{"issue":"11","key":"4330_CR80","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346\u201358.","journal-title":"Nat Immunol"},{"issue":"5899","key":"4330_CR81","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271\u20135.","journal-title":"Science"},{"issue":"29","key":"4330_CR82","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1073\/pnas.0711106105","volume":"105","author":"Y Onishi","year":"2008","unstructured":"Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4330_CR83","doi-asserted-by":"publisher","first-page":"102884","DOI":"10.1016\/j.redox.2023.102884","volume":"67","author":"P Wang","year":"2023","unstructured":"Wang P, Gao R, Wu T, Zhang J, Sun X, Fan F, et al. Accumulation of endogenous adenosine improves cardiomyocyte metabolism via epigenetic reprogramming in an ischemia-reperfusion model. Redox Biol. 2023;67:102884.","journal-title":"Redox Biol"},{"issue":"9","key":"4330_CR84","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s42255-024-01115-7","volume":"6","author":"SR Sukka","year":"2024","unstructured":"Sukka SR, Ampomah PB, Darville LNF, Ngai D, Wang X, Kuriakose G, et al. Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution. Nat Metab. 2024;6(9):1736\u201355.","journal-title":"Nat Metab"},{"issue":"7","key":"4330_CR85","doi-asserted-by":"publisher","first-page":"e004037","DOI":"10.1136\/jitc-2021-004037","volume":"10","author":"B Deng","year":"2022","unstructured":"Deng B, Yang B, Chen J, Wang S, Zhang W, Guo Y, et al. Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy. J Immunother Cancer. 2022;10(7):e004037.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4330_CR86","doi-asserted-by":"publisher","first-page":"115172","DOI":"10.1016\/j.celrep.2024.115172","volume":"44","author":"JE Toller-Kawahisa","year":"2025","unstructured":"Toller-Kawahisa JE, Viacava PR, Palsson-McDermott EM, Nascimento DC, Cervantes-Silva MP, O\u2019Carroll SM, et al. Metabolic reprogramming of macrophages by PKM2 promotes IL-10 production via adenosine. Cell Rep. 2025;44(1):115172.","journal-title":"Cell Rep"},{"key":"4330_CR87","doi-asserted-by":"publisher","first-page":"173090","DOI":"10.1016\/j.ejphar.2020.173090","volume":"877","author":"C Yunna","year":"2020","unstructured":"Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1\/M2 polarization. Eur J Pharmacol. 2020;877:173090.","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"4330_CR88","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369.","journal-title":"Cancer Res"},{"issue":"4","key":"4330_CR89","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","volume":"22","author":"A Sasaki","year":"2019","unstructured":"Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22(4):793\u2013802.","journal-title":"Gastric Cancer"},{"key":"4330_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","volume":"321","author":"M Li","year":"2020","unstructured":"Li M, Li M, Yang Y, Liu Y, Xie H, Yu Q, et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-gamma and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. J Controll Release Off J Controlled Release Soc. 2020;321:23\u201335.","journal-title":"J Controll Release Off J Controlled Release Soc"},{"issue":"731","key":"4330_CR91","doi-asserted-by":"publisher","first-page":"eadd1834","DOI":"10.1126\/scitranslmed.add1834","volume":"16","author":"A Voissiere","year":"2024","unstructured":"Voissiere A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, et al. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med. 2024;16(731):eadd1834.","journal-title":"Sci Transl Med"},{"issue":"19","key":"4330_CR92","doi-asserted-by":"publisher","first-page":"e25773","DOI":"10.1097\/MD.0000000000025773","volume":"100","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi K, Tsuchihashi K, Tsuji K, Kito Y, Tanoue K, Ohmura H, et al. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: a case report. Medicine (Baltimore). 2021;100(19):e25773.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4330_CR93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00018-022-04137-0","volume":"79","author":"Q Wu","year":"2022","unstructured":"Wu Q, Sun S, Wei L, Liu M, Liu H, Liu T, et al. Twist1 regulates macrophage plasticity to promote renal fibrosis through galectin-3. Cell Mol Life Sci. 2022;79(3):137.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"4330_CR94","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/ijms20071607","volume":"20","author":"C Capalbo","year":"2019","unstructured":"Capalbo C, Scafetta G, Filetti M, Marchetti P, Bartolazzi A. Predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in NSCLCs. Int J Mol Sci. 2019;20(7):1607.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"4330_CR95","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-17-0740","volume":"77","author":"P Lamichhane","year":"2017","unstructured":"Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, et al. IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 2017;77(23):6667\u201378.","journal-title":"Cancer Res"},{"issue":"8","key":"4330_CR96","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","volume":"75","author":"Z Sun","year":"2015","unstructured":"Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 2015;75(8):1635\u201344.","journal-title":"Cancer Res"},{"issue":"3","key":"4330_CR97","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017;168(3):542.","journal-title":"Cell"},{"issue":"1","key":"4330_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","volume":"5","author":"X Wu","year":"2017","unstructured":"Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, et al. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol Res. 2017;5(1):17\u201328.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"4330_CR99","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"30","key":"4330_CR100","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1073\/pnas.1007394107","volume":"107","author":"E Lazar-Molnar","year":"2010","unstructured":"Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010;107(30):13402\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4330_CR101","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4049\/jimmunol.181.3.2189","volume":"181","author":"CA Fielding","year":"2008","unstructured":"Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, Grail D, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol. 2008;181(3):2189\u201395.","journal-title":"J Immunol"},{"issue":"10","key":"4330_CR102","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763\u201376.","journal-title":"Nat Rev Drug Discov"},{"key":"4330_CR103","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.1038\/ncomms14381","volume":"8","author":"J Kargl","year":"2017","unstructured":"Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381.","journal-title":"Nat Commun"},{"issue":"7","key":"4330_CR104","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073\u201381.","journal-title":"Carcinogenesis"},{"key":"4330_CR105","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.isci.2018.10.021","volume":"9","author":"D Xiong","year":"2018","unstructured":"Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer. iScience. 2018;9:258\u201377.","journal-title":"iScience"},{"issue":"6","key":"4330_CR106","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s44318-024-00051-2","volume":"43","author":"Z Wang","year":"2024","unstructured":"Wang Z, Yan M, Ye L, Zhou Q, Duan Y, Jiang H, et al. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation. EMBO J. 2024;43(6):931\u201355.","journal-title":"EMBO J"},{"issue":"1","key":"4330_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","volume":"8","author":"J Hu","year":"2023","unstructured":"Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, et al. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023;8(1):155.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4330_CR108","doi-asserted-by":"publisher","first-page":"eadr6375","DOI":"10.1126\/sciadv.adr6375","volume":"11","author":"J Pal","year":"2025","unstructured":"Pal J, Riester M, Ganner A, Ghosh A, Dhamija S, Mookherjee D, et al. Nonstop mutations cause loss of renal tumor suppressor proteins VHL and BAP1 and affect multiple stages of protein translation. Sci Adv. 2025;11(7):eadr6375.","journal-title":"Sci Adv"},{"issue":"1","key":"4330_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/HEP.0000000000000704","volume":"81","author":"C Yin","year":"2025","unstructured":"Yin C, Zhang C, Wang Y, Liu G, Wang N, Liang N, et al. ALDOB\/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis. Hepatology. 2025;81(1):77\u201393.","journal-title":"Hepatology"},{"issue":"9","key":"4330_CR110","doi-asserted-by":"publisher","first-page":"101538","DOI":"10.1016\/j.jcmgh.2025.101538","volume":"19","author":"J Zhang","year":"2025","unstructured":"Zhang J, Wang S, Yu J, Li B, Wang S, Suo N, et al. A dual role of HGF-ERK signaling in IL6\/HGF-induced hepatocyte proliferation. Cell Mol Gastroenterol Hepatol. 2025;19(9):101538.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"4330_CR111","doi-asserted-by":"publisher","first-page":"19583","DOI":"10.1038\/s41598-024-68048-9","volume":"14","author":"J Du","year":"2024","unstructured":"Du J, Huang Z. NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma. Sci Rep. 2024;14(1):19583.","journal-title":"Sci Rep"},{"issue":"2","key":"4330_CR112","doi-asserted-by":"publisher","first-page":"e0193018","DOI":"10.1371\/journal.pone.0193018","volume":"13","author":"T Kiriu","year":"2018","unstructured":"Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. 2018;13(2):e0193018.","journal-title":"PLoS ONE"},{"issue":"8","key":"4330_CR113","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519\u201331.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"4330_CR114","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4330_CR115","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/hepr.13741","volume":"52","author":"K Maesaka","year":"2022","unstructured":"Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K, et al. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res Off J Jpn Soc Hepatol. 2022;52(3):298\u2013307.","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"3","key":"4330_CR116","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4143\/crt.2020.824","volume":"53","author":"YG Lee","year":"2021","unstructured":"Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, et al. Outcomes and biomarkers of immune checkpoint inhibitor therapy in patients with refractory head and neck squamous cell carcinoma: KCSG HN18-12. Cancer Res Treat. 2021;53(3):671\u20137.","journal-title":"Cancer Res Treat"},{"key":"4330_CR117","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.18632\/oncotarget.28316","volume":"13","author":"A Karabajakian","year":"2022","unstructured":"Karabajakian A, Garrivier T, Crozes C, Gadot N, Blay JY, Berard F, et al. Addendum: hyperprogression and impact of tumor growth kinetics after PD1\/PDL1 inhibition in head and neck squamous cell carcinoma. Oncotarget. 2022;13:1305.","journal-title":"Oncotarget"},{"issue":"6","key":"4330_CR118","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cllc.2024.06.006","volume":"25","author":"AT Shah","year":"2024","unstructured":"Shah AT, Blanchard I, Padda SK, Wakelee HA, Neal JW. Molecular characteristics and pretreatment neutrophil-to-lymphocyte ratio as predictors of durable clinical benefit from immune checkpoint inhibition in non-small cell lung cancer. Clin Lung Cancer. 2024;25(6):550\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"4330_CR119","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12876-025-04028-1","volume":"25","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Jiang Z, Ye T, Yu L, Wang Q, Lin P, et al. Prognostic value of platelet-to-lymphocyte ratio in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):437.","journal-title":"BMC Gastroenterol"},{"key":"4330_CR120","doi-asserted-by":"publisher","first-page":"1293680","DOI":"10.3389\/fonc.2024.1293680","volume":"14","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu W, Sun B, Guo T, Si K, Zheng C, et al. Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors. Front Oncol. 2024;14:1293680.","journal-title":"Front Oncol"},{"issue":"1","key":"4330_CR121","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4330_CR122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-025-00676-x","volume":"14","author":"C Cai","year":"2025","unstructured":"Cai C, Liu Y, Lu R, Fan X, Zeng S, Gan P. Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities. Exp Hematol Oncol. 2025;14(1):83.","journal-title":"Exp Hematol Oncol"},{"key":"4330_CR123","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02303-7","author":"M Ahmed","year":"2025","unstructured":"Ahmed M, Yuan P, Lei JG, Tang ZM, Yang ZR, Potempa LA, et al. From homeostasis to inflammation to autoimmunity: the potential impact of CRP. Inflammation. 2025. https:\/\/doi.org\/10.1007\/s10753-025-02303-7.","journal-title":"Inflammation"},{"issue":"2","key":"4330_CR124","doi-asserted-by":"publisher","first-page":"e70175","DOI":"10.1002\/ctm2.70175","volume":"15","author":"H Ke","year":"2025","unstructured":"Ke H, Li P, Li Z, Zeng X, Zhang C, Luo S, et al. Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells. Clin Transl Med. 2025;15(2):e70175.","journal-title":"Clin Transl Med"},{"issue":"7","key":"4330_CR125","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","volume":"22","author":"Z Rahal","year":"2025","unstructured":"Rahal Z, El Darzi R, Moghaddam SJ, Cascone T, Kadara H. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol. 2025;22(7):463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"4330_CR126","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188(11):3081-96 e19.","journal-title":"Cell"},{"issue":"29","key":"4330_CR127","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(29):3383\u201393.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4330_CR128","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1158\/1541-7786.MCR-12-0160","volume":"10","author":"MY Ho","year":"2012","unstructured":"Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, et al. TNF-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3beta-dependent mechanism. Mol Cancer Res. 2012;10(8):1109\u201319.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"4330_CR129","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/biomedicines11030694","volume":"11","author":"S Laurino","year":"2023","unstructured":"Laurino S, Brancaccio M, Angrisano T, Calice G, Russi S, Mazzone P, et al. Role of IL-6\/STAT3 axis in resistance to cisplatin in gastric cancers. Biomedicines. 2023;11(3):694.","journal-title":"Biomedicines"},{"issue":"7","key":"4330_CR130","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41419-024-06795-3","volume":"15","author":"R Tatsuno","year":"2024","unstructured":"Tatsuno R, Ichikawa J, Komohara Y, Pan C, Kawasaki T, Enomoto A, et al. Correction: pivotal role of IL-8 derived from the interaction between osteosarcoma and tumor-associated macrophages in osteosarcoma growth and metastasis via the FAK pathway. Cell Death Dis. 2024;15(7):471.","journal-title":"Cell Death Dis"},{"issue":"5","key":"4330_CR131","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","volume":"26","author":"Z Bakouny","year":"2020","unstructured":"Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat Med. 2020;26(5):650\u20131.","journal-title":"Nat Med"},{"issue":"2","key":"4330_CR132","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"2","key":"4330_CR133","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4330_CR134","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-024-01004-x","volume":"31","author":"D Sun","year":"2024","unstructured":"Sun D, Qian H, Li J, Xing P. Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy. J Biomed Sci. 2024;31(1):17.","journal-title":"J Biomed Sci"},{"issue":"44","key":"4330_CR135","doi-asserted-by":"publisher","first-page":"e2102420118","DOI":"10.1073\/pnas.2102420118","volume":"118","author":"AM Klein","year":"2021","unstructured":"Klein AM, Biderman L, Tong D, Alaghebandan B, Plumber SA, Mueller HS, et al. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Proc Nat Acad Sci USA. 2021;118(44):e2102420118.","journal-title":"Proc Nat Acad Sci USA"},{"issue":"8","key":"4330_CR136","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/cells14080583","volume":"14","author":"Y Huang","year":"2025","unstructured":"Huang Y, Li W, Zhou Y, Bai J, Li N, Su Z, et al. Strategies for p53 activation and targeted inhibitors of the p53-Mdm2\/MdmX interaction. Cells. 2025;14(8):583.","journal-title":"Cells"},{"key":"4330_CR137","doi-asserted-by":"publisher","first-page":"117909","DOI":"10.1016\/j.ejmech.2025.117909","volume":"297","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang S, Irakoze LM, Zhao Y. Targeting p53 activation: recent therapeutic advances in cancer and diabetic macular edema. Eur J Med Chem. 2025;297:117909.","journal-title":"Eur J Med Chem"},{"key":"4330_CR138","doi-asserted-by":"publisher","first-page":"104834","DOI":"10.1016\/j.critrevonc.2025.104834","volume":"214","author":"G Di Grazia","year":"2025","unstructured":"Di Grazia G, Conti C, Nucera S, Stella S, Massimino M, Giuliano M, et al. Bridging the gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer. Crit Rev Oncol Hematol. 2025;214:104834.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4330_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01541-4","author":"C Xie","year":"2025","unstructured":"Xie C, Liang XL, Chen B, Chen S, Xiong FX, Wang QC, et al. hMTR4 promotes p53 protein degradation and tumor growth by accelerating rRNA processing and regulating the RPL5-MDM2 axis. Cell Death Diff. 2025. https:\/\/doi.org\/10.1038\/s41418-025-01541-4.","journal-title":"Cell Death Diff"},{"issue":"10","key":"4330_CR140","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.immuni.2024.08.015","volume":"57","author":"Z Nian","year":"2024","unstructured":"Nian Z, Dou Y, Shen Y, Liu J, Du X, Jiang Y, et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity. 2024;57(10):2344-61 e7.","journal-title":"Immunity"},{"key":"4330_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.06.008","author":"AC Minor","year":"2025","unstructured":"Minor AC, Couser E, Eichner LJ. Targeting LKB1\/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance. Trends Pharmacol Sci. 2025. https:\/\/doi.org\/10.1016\/j.tips.2025.06.008.","journal-title":"Trends Pharmacol Sci"},{"key":"4330_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02837-8","author":"K Morimoto","year":"2025","unstructured":"Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, et al. Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study. Int J Clin Oncol. 2025. https:\/\/doi.org\/10.1007\/s10147-025-02837-8.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"4330_CR143","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41388-021-02124-6","volume":"41","author":"Y Lu","year":"2022","unstructured":"Lu Y, Wu F, Cao Q, Sun Y, Huang M, Xiao J, et al. B7\u2013H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. Oncogene. 2022;41(5):704\u201317.","journal-title":"Oncogene"},{"issue":"1","key":"4330_CR144","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1038\/s41598-024-74779-6","volume":"15","author":"D Yin","year":"2025","unstructured":"Yin D, Lu X, Liang X, Lu Y, Xiong L, Wu P, et al. STK11 genetic alterations in metastatic EGFR mutant lung cancer. Sci Rep. 2025;15(1):5729.","journal-title":"Sci Rep"},{"issue":"9","key":"4330_CR145","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s12094-021-02579-9","volume":"23","author":"J Liu","year":"2021","unstructured":"Liu J, Wu Q, Wu S, Xie X. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). Clin Transl Oncol. 2021;23(9):1782\u201393.","journal-title":"Clin Transl Oncol"},{"issue":"17","key":"4330_CR146","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1038\/s41388-020-1227-2","volume":"39","author":"F Li","year":"2020","unstructured":"Li F, Li Z, Han Q, Cheng Y, Ji W, Yang Y, et al. Enhanced autocrine FGF19\/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. Oncogene. 2020;39(17):3507\u201321.","journal-title":"Oncogene"},{"issue":"20","key":"4330_CR147","doi-asserted-by":"publisher","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","volume":"63","author":"R Rezende Miranda","year":"2020","unstructured":"Rezende Miranda R, Fu Y, Chen X, Perino J, Cao P, Carpten J, et al. Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma. J Med Chem. 2020;63(20):11484\u201397.","journal-title":"J Med Chem"},{"issue":"3-4","key":"4330_CR148","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41417-019-0135-5","volume":"27","author":"YM Liao","year":"2020","unstructured":"Liao YM, Song Y, Li YK, Du JH, Zhou Y. SOX17, beta-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression. Cancer Gene Ther. 2020;27(3\u20134):256\u201363.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"4330_CR149","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12282-020-01150-8","volume":"28","author":"R Ogata","year":"2021","unstructured":"Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J. Resistance to cyclin-dependent kinase (CDK) 4\/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Breast Cancer. 2021;28(1):206\u201315.","journal-title":"Breast Cancer"},{"issue":"9","key":"4330_CR150","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11655-020-3193-5","volume":"27","author":"A Mari","year":"2021","unstructured":"Mari A, Mani G, Nagabhishek SN, Balaraman G, Subramanian N, Mirza FB, et al. Carvacrol promotes cell cycle arrest and apoptosis through PI3K\/AKT signaling pathway in MCF-7 breast cancer cells. Chin J Integr Med. 2021;27(9):680\u20137.","journal-title":"Chin J Integr Med"},{"issue":"8","key":"4330_CR151","doi-asserted-by":"publisher","first-page":"13182","DOI":"10.1002\/jcp.27989","volume":"234","author":"F Wang","year":"2019","unstructured":"Wang F, Mao A, Tang J, Zhang Q, Yan J, Wang Y, et al. microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1\/E1-pRb-E2F1 pathway in prostate cancer cells. J Cell Physiol. 2019;234(8):13182\u201390.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4330_CR152","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2018.10.027","volume":"152","author":"Q Zhong","year":"2019","unstructured":"Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. Gynecol Oncol. 2019;152(1):157\u201365.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4330_CR153","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1038\/s41467-020-19349-w","volume":"11","author":"Q Shi","year":"2020","unstructured":"Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11(1):5513.","journal-title":"Nat Commun"},{"issue":"21","key":"4330_CR154","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","volume":"25","author":"J Yu","year":"2019","unstructured":"Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019;25(21):6511\u201323.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4330_CR155","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4\/6 inhibitor abemaciclib induces a t cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978\u201394.","journal-title":"Cell Rep"},{"issue":"12","key":"4330_CR156","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","volume":"9","author":"FI Montalto","year":"2020","unstructured":"Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells. 2020;9(12):2648.","journal-title":"Cells"},{"key":"4330_CR157","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3389\/fimmu.2020.01620","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Huang Y, Gao X, Li Y, Lin J, Chen L, et al. CCND1 amplification contributes to immunosuppression and is associated with a poor prognosis to immune checkpoint inhibitors in solid tumors. Front Immunol. 2020;11:1620.","journal-title":"Front Immunol"},{"issue":"2","key":"4330_CR158","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"6257","key":"4330_CR159","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311.","journal-title":"Science"},{"issue":"23","key":"4330_CR160","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"12","key":"4330_CR161","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"1","key":"4330_CR162","first-page":"848","volume":"18","author":"T Jiang","year":"2018","unstructured":"Jiang T, Liu J, Mu J. Downregulation of microRNA\u2011449a\u20115p promotes esophageal squamous cell carcinoma cell proliferation via cyclin D1 regulation. Mol Med Rep. 2018;18(1):848\u201354.","journal-title":"Mol Med Rep"},{"issue":"8","key":"4330_CR163","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neo.2021.05.016","volume":"23","author":"M Pariyar","year":"2021","unstructured":"Pariyar M, Johns A, Thorne RF, Scott RJ, Avery-Kiejda KA. Copy number variation in triple negative breast cancer samples associated with lymph node metastasis. Neoplasia. 2021;23(8):743\u201353.","journal-title":"Neoplasia"},{"issue":"1","key":"4330_CR164","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181.","journal-title":"Signal Transduct Target Ther"},{"key":"4330_CR165","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","volume":"179","author":"M Presta","year":"2017","unstructured":"Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171\u201387.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"4330_CR166","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4330_CR167","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1158\/1078-0432.CCR-18-4267","volume":"25","author":"AB Hanker","year":"2019","unstructured":"Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, et al. Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin Cancer Res. 2019;25(4):1434.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4330_CR168","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82(1):114\u201329.","journal-title":"Cancer Res"},{"issue":"9","key":"4330_CR169","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14737140.2018.1491795","volume":"18","author":"GC Ghedini","year":"2018","unstructured":"Ghedini GC, Ronca R, Presta M, Giacomini A. Future applications of FGF\/FGFR inhibitors in cancer. Expert Rev Anticancer Ther. 2018;18(9):861\u201372.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"4330_CR170","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019;76(5):599\u2013603.","journal-title":"Eur Urol"},{"issue":"10","key":"4330_CR171","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.4049\/jimmunol.1801199","volume":"202","author":"P Li","year":"2019","unstructured":"Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK\/STAT3 signaling pathway. J Immunol. 2019;202(10):3065\u201375.","journal-title":"J Immunol"},{"issue":"9","key":"4330_CR172","doi-asserted-by":"publisher","first-page":"e3035","DOI":"10.1038\/cddis.2017.433","volume":"8","author":"Y Yuan","year":"2017","unstructured":"Yuan Y, Xie X, Jiang Y, Wei Z, Wang P, Chen F, et al. LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis. 2017;8(9):e3035.","journal-title":"Cell Death Dis"},{"issue":"12","key":"4330_CR173","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1242\/dev.01137","volume":"131","author":"OG Kelly","year":"2004","unstructured":"Kelly OG, Pinson KI, Skarnes WC. The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development. 2004;131(12):2803\u201315.","journal-title":"Development"},{"issue":"2","key":"4330_CR174","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cytogfr.2005.01.007","volume":"16","author":"L Dailey","year":"2005","unstructured":"Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005;16(2):233\u201347.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"4330_CR175","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcp.22214","volume":"225","author":"VM Ding","year":"2010","unstructured":"Ding VM, Ling L, Natarajan S, Yap MG, Cool SM, Choo AB. FGF-2 modulates Wnt signaling in undifferentiated hESC and iPS cells through activated PI3-K\/GSK3beta signaling. J Cell Physiol. 2010;225(2):417\u201328.","journal-title":"J Cell Physiol"},{"issue":"24","key":"4330_CR176","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","volume":"83","author":"Y Ouyang","year":"2023","unstructured":"Ouyang Y, Ou Z, Zhong W, Yang J, Fu S, Ouyang N, et al. FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation. Cancer Res. 2023;83(24):4030\u201346.","journal-title":"Cancer Res"},{"key":"4330_CR177","doi-asserted-by":"publisher","first-page":"1358019","DOI":"10.3389\/fimmu.2024.1358019","volume":"15","author":"DR Bergman","year":"2024","unstructured":"Bergman DR, Wang Y, Trujillo E, Fernald AA, Li L, Pearson AT, et al. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024;15:1358019.","journal-title":"Front Immunol"},{"issue":"1","key":"4330_CR178","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The Impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22(1):185.","journal-title":"Mol Cancer"},{"issue":"1","key":"4330_CR179","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41419-025-07821-8","volume":"16","author":"YC Lin","year":"2025","unstructured":"Lin YC, Chu CY, Hsieh TH, Lin BJ, Liou JP, Yen Y, et al. FGFR inhibitors promote the autophagic degradation of IFN-gamma-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer. Cell Death Dis. 2025;16(1):485.","journal-title":"Cell Death Dis"},{"key":"4330_CR180","doi-asserted-by":"publisher","first-page":"e2300406","DOI":"10.1200\/PO.23.00406","volume":"8","author":"J Gong","year":"2024","unstructured":"Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, et al. Phase II study of erdafitinib in patients with tumors with FGFR amplifications: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K1. JCO Precis Oncol. 2024;8:e2300406.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"4330_CR181","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2024.3900","volume":"10","author":"RF Sweis","year":"2024","unstructured":"Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, et al. Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: the FORT-2 phase 1b nonrandomized clinical trial. JAMA Oncol. 2024;10(11):1565\u201370.","journal-title":"JAMA Oncol"},{"issue":"7","key":"4330_CR182","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/2159-8290.CD-14-1096","volume":"5","author":"M Jafri","year":"2015","unstructured":"Jafri M, Wake NC, Ascher DB, Pires DE, Gentle D, Morris MR, et al. Germline mutations in the CDKN2B tumor suppressor gene predispose to renal cell carcinoma. Cancer Discov. 2015;5(7):723\u20139.","journal-title":"Cancer Discov"},{"key":"4330_CR183","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"issue":"12","key":"4330_CR184","first-page":"1519","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519\u201328.","journal-title":"Neuro Oncol"},{"issue":"5","key":"4330_CR185","first-page":"860","volume":"12","author":"SW Aesif","year":"2017","unstructured":"Aesif SW, Aubry MC, Yi ES, Kloft-Nelson SM, Jenkins SM, Spears GM, et al. Loss of p16(INK4A) expression and homozygous CDKN2A deletion are associated with worse outcome and younger age in thymic carcinomas. J Thorac Oncol Official Publ Int Assoc Study Lung Cancer. 2017;12(5):860\u201371.","journal-title":"J Thorac Oncol Official Publ Int Assoc Study Lung Cancer"},{"issue":"1","key":"4330_CR186","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/onc.2017.316","volume":"37","author":"Q Tu","year":"2018","unstructured":"Tu Q, Hao J, Zhou X, Yan L, Dai H, Sun B, et al. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. Oncogene. 2018;37(1):128\u201338.","journal-title":"Oncogene"},{"issue":"1","key":"4330_CR187","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-018-0639-8","volume":"11","author":"E Genesca","year":"2018","unstructured":"Genesca E, Lazarenkov A, Morgades M, Berbis G, Ruiz-Xiville N, Gomez-Marzo P, et al. Frequency and clinical impact of CDKN2A\/ARF\/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018;11(1):96.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4330_CR188","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1878-0261.13206","volume":"16","author":"Y Peng","year":"2022","unstructured":"Peng Y, Chen Y, Song M, Zhang X, Li P, Yu X, et al. Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Mol Oncol. 2022;16(8):1746\u201360.","journal-title":"Mol Oncol"},{"issue":"1","key":"4330_CR189","doi-asserted-by":"publisher","first-page":"507","DOI":"10.21037\/jtd-23-1017","volume":"16","author":"L Zhao","year":"2024","unstructured":"Zhao L, Zhou X, Li H, Yin T, Jiang Y. Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function. J Thorac Dis. 2024;16(1):507\u201315.","journal-title":"J Thorac Dis"},{"key":"4330_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.018","author":"I Dagogo-Jack","year":"2025","unstructured":"Dagogo-Jack I, Mitchell O, Codd E, Li A, Mitchell D, Flynn SE, et al. Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol Official Publ Int Assoc Study Lung Cancer. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.018.","journal-title":"J Thorac Oncol Official Publ Int Assoc Study Lung Cancer"},{"issue":"1","key":"4330_CR191","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10142-025-01657-3","volume":"25","author":"R Gu","year":"2025","unstructured":"Gu R, Li S, Yu B, Gu J, Guan B, Wu H. Increased CDKN2A expression correlates with resistance to platinum-based therapy and decreased infiltration of B lymphocytes in colon adenocarcinoma. Funct Integr Genomics. 2025;25(1):144.","journal-title":"Funct Integr Genomics"},{"issue":"29","key":"4330_CR192","doi-asserted-by":"publisher","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, et al. Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022;8(29):eabm8780.","journal-title":"Sci Adv"},{"issue":"6","key":"4330_CR193","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","volume":"10","author":"N Muthalagu","year":"2020","unstructured":"Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 2020;10(6):872\u201387.","journal-title":"Cancer Discov"},{"issue":"1","key":"4330_CR194","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41467-020-14632-2","volume":"11","author":"E Galvani","year":"2020","unstructured":"Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, et al. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020;11(1):853.","journal-title":"Nat Commun"},{"issue":"9","key":"4330_CR195","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41422-019-0212-1","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, et al. Author correction: Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):777.","journal-title":"Cell Res"},{"issue":"3","key":"4330_CR196","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-24-1817","volume":"85","author":"S Wang","year":"2025","unstructured":"Wang S, Lai JC, Li Y, Tang C, Lu J, Han M, et al. Loss of CDKN2A enhances the efficacy of immunotherapy in EGFR-mutant non-small cell lung cancer. Cancer Res. 2025;85(3):585\u2013601.","journal-title":"Cancer Res"},{"issue":"20","key":"4330_CR197","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-22-1598","volume":"28","author":"HA Gamlen","year":"2022","unstructured":"Gamlen HA, Romer-Seibert JS, Lawler ME, Versace AM, Goetz ML, Feng Y, et al. miR-196b-TLR7\/8 signaling axis regulates innate immune signaling and myeloid maturation in DNMT3A-mutant AML. Clin Cancer Res. 2022;28(20):4574\u201386.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4330_CR198","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00262-024-03717-2","volume":"73","author":"P Zhang","year":"2024","unstructured":"Zhang P, Wan Y, Ma J, Gong J, Zhong Z, Cui Y, et al. Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment. Cancer Immunol Immunother. 2024;73(7):127.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4330_CR199","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-023-01534-5","volume":"15","author":"G Kerdivel","year":"2023","unstructured":"Kerdivel G, Amrouche F, Calmejane MA, Carallis F, Hamroune J, Hantel C, et al. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma. Clin Epigenetics. 2023;15(1):121.","journal-title":"Clin Epigenetics"},{"issue":"620","key":"4330_CR200","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Zebley CC, Petersen CT, Fan Y, Anido AA, Yi Z, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13(620):eabh0272.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4330_CR201","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","volume":"128","author":"WT Abplanalp","year":"2021","unstructured":"Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ Res. 2021;128(2):216\u201328.","journal-title":"Circ Res"},{"issue":"7959","key":"4330_CR202","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","volume":"617","author":"JS Bergholz","year":"2023","unstructured":"Bergholz JS, Wang Q, Wang Q, Ramseier M, Prakadan S, Wang W, et al. PI3Kbeta controls immune evasion in PTEN-deficient breast tumours. Nature. 2023;617(7959):139\u201346.","journal-title":"Nature"},{"issue":"7484","key":"4330_CR203","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501.","journal-title":"Nature"},{"issue":"38","key":"4330_CR204","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/onc.2013.409","volume":"33","author":"Y Dong","year":"2014","unstructured":"Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene. 2014;33(38):4632\u201342.","journal-title":"Oncogene"},{"issue":"3","key":"4330_CR205","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.3311","volume":"17","author":"S Li","year":"2016","unstructured":"Li S, Zhu M, Pan R, Fang T, Cao YY, Chen S, et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat Immunol. 2016;17(3):241\u20139.","journal-title":"Nat Immunol"},{"issue":"2","key":"4330_CR206","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN Is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197\u2013204.","journal-title":"Immunity"},{"issue":"2","key":"4330_CR207","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"23","key":"4330_CR208","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1016\/j.devcel.2024.08.003","volume":"59","author":"C Zhang","year":"2024","unstructured":"Zhang C, Ma HM, Wu S, Shen JM, Zhang N, Xu YL, et al. Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression. Dev Cell. 2024;59(23):3072-88 e8.","journal-title":"Dev Cell"},{"issue":"6","key":"4330_CR209","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","volume":"35","author":"P Chen","year":"2019","unstructured":"Chen P, Zhao D, Li J, Liang X, Li J, Chang A, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell. 2019;35(6):868-84 e6.","journal-title":"Cancer Cell"},{"issue":"7538","key":"4330_CR210","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature. 2015;518(7538):240\u20134.","journal-title":"Nature"},{"issue":"6","key":"4330_CR211","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.7150\/ijbs.91867","volume":"20","author":"G Ren","year":"2024","unstructured":"Ren G, Chen J, Pu Y, Yang EJ, Tao S, Mou PK, et al. BET inhibition induces synthetic lethality in PTEN deficient colorectal cancers via dual action on p21(CIP1\/WAF1). Int J Biol Sci. 2024;20(6):1978\u201391.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"4330_CR212","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3892\/or.2016.5030","volume":"36","author":"J Xiong","year":"2016","unstructured":"Xiong J, Li Z, Zhang Y, Li D, Zhang G, Luo X, et al. PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K\/Akt signaling pathway by regulating PTEN. Oncol Rep. 2016;36(4):1819\u201328.","journal-title":"Oncol Rep"},{"issue":"22","key":"4330_CR213","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/0008-5472.CAN-23-3890","volume":"84","author":"S Spear","year":"2024","unstructured":"Spear S, Le Saux O, Mirza HB, Iyer N, Tyson K, Grundland Freile F, et al. PTEN loss shapes macrophage dynamics in high-grade serous ovarian carcinoma. Cancer Res. 2024;84(22):3772\u201387.","journal-title":"Cancer Res"},{"issue":"1","key":"4330_CR214","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41467-022-30444-y","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Xu Y, Chen Q, Zhang H, Zeng Y, Geng Y, et al. The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells. Nat Commun. 2022;13(1):2762.","journal-title":"Nat Commun"},{"key":"4330_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102291","author":"X Sun","year":"2025","unstructured":"Sun X, Cai X, Li S, Pi R, Guo Z, Jiang J, et al. High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102291.","journal-title":"Cell Rep Med"},{"issue":"3","key":"4330_CR216","doi-asserted-by":"publisher","first-page":"e010529","DOI":"10.1136\/jitc-2024-010529","volume":"13","author":"H Zang","year":"2025","unstructured":"Zang H, Liu T, Wang X, Cheng S, Zhu X, Huang C, et al. PD-1(IR2) promotes tumor evasion via deregulating CD8(+) T cell function. J Immunother Cancer. 2025;13(3):e010529.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4330_CR217","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/jitc-2019-000154","volume":"8","author":"D Chen","year":"2020","unstructured":"Chen D, Li G, Ji C, Lu Q, Qi Y, Tang C, et al. Enhanced B7\u2013H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. J Immunother Cancer. 2020;8(1):e000154.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4330_CR218","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi W, Liu N, Liu Z, Yang Y, Zeng Q, Wang Y, et al. Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep Med. 2024;5(5):101531.","journal-title":"Cell Rep Med"},{"issue":"12","key":"4330_CR219","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s00432-020-03316-5","volume":"146","author":"JH Park","year":"2020","unstructured":"Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, et al. Hyperprogressive disease and its clinical impact in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18\u201312. J Cancer Res Clin Oncol. 2020;146(12):3359\u201369.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"4330_CR220","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","volume":"14","author":"CN Jenne","year":"2013","unstructured":"Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996\u20131006.","journal-title":"Nat Immunol"},{"issue":"1","key":"4330_CR221","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152\u201364.","journal-title":"Nat Med"},{"key":"4330_CR222","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2025.2526682","author":"P Guglielmo","year":"2025","unstructured":"Guglielmo P, Olivieri M, Filippi L, Marzo K, Jandric J, Rodari M, et al. Liver metastases in breast cancer: [18F]FDG and radioembolization as strategies for diagnosis and treatment. Expert Rev Med Dev. 2025. https:\/\/doi.org\/10.1080\/17434440.2025.2526682.","journal-title":"Expert Rev Med Dev"},{"key":"4330_CR223","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2018","unstructured":"Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1\u20139.","journal-title":"Eur J Cancer"},{"key":"4330_CR224","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf192","author":"HJ Lenz","year":"2025","unstructured":"Lenz HJ, Lunacsek O, Ostojic H, Pan X, Dochy E, Vassilev Z, et al. Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf192.","journal-title":"Oncologist"},{"issue":"3","key":"4330_CR225","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000183250","volume":"67","author":"MI Koukourakis","year":"2009","unstructured":"Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V. Serum and tissue LDH levels in patients with breast\/gynaecological cancer and benign diseases. Gynecol Obstet Invest. 2009;67(3):162\u20138.","journal-title":"Gynecol Obstet Invest"},{"issue":"12","key":"4330_CR226","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1007\/s12094-024-03696-x","volume":"26","author":"GA Sen","year":"2024","unstructured":"Sen GA, Oztas NS, Degerli E, Guliyev M, Can G, Turna H, et al. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors. Clin Transl Oncol. 2024;26(12):3264\u201371.","journal-title":"Clin Transl Oncol"},{"key":"4330_CR227","doi-asserted-by":"publisher","first-page":"843707","DOI":"10.3389\/fonc.2022.843707","volume":"12","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Bian J, Zhang J, Zhang T, Lu X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2022;12:843707.","journal-title":"Front Oncol"},{"key":"4330_CR228","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175171","author":"HC Yildirim","year":"2022","unstructured":"Yildirim HC, Guven DC, Aktepe OH, Taban H, Yilmaz F, Yasar S, et al. Blood based biomarkers as predictive factors for hyperprogressive disease. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11175171.","journal-title":"J Clin Med"},{"issue":"6614","key":"4330_CR229","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. Science. 2022;377(6614):1519\u201329.","journal-title":"Science"},{"key":"4330_CR230","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.jaut.2023.103160","volume":"143","author":"X Peng","year":"2024","unstructured":"Peng X, Li H, Zhu L, Zhao S, Li Z, Li S, et al. Single-cell sequencing of the retina shows that LDHA regulates pathogenesis of autoimmune uveitis. J Autoimmun. 2024;143:103160.","journal-title":"J Autoimmun"},{"issue":"5","key":"4330_CR231","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2019.0138","volume":"5","author":"R Ferrara","year":"2019","unstructured":"Ferrara R, Caramella C, Besse B. Hyperprogression-immunotherapy-related phenomenon vs intrinsic natural history of cancer-in reply. JAMA Oncol. 2019;5(5):744.","journal-title":"JAMA Oncol"},{"key":"4330_CR232","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.05.033","volume":"134","author":"D Lang","year":"2019","unstructured":"Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K, et al. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1\/PD-L1 inhibitor treated advanced NSCLC-a retrospective cohort study. Lung Cancer. 2019;134:59\u201365.","journal-title":"Lung Cancer"},{"issue":"1","key":"4330_CR233","doi-asserted-by":"publisher","first-page":"2531255","DOI":"10.1080\/07853890.2025.2531255","volume":"57","author":"W Ma","year":"2025","unstructured":"Ma W, Shi Q, Su X, Zhang L, Chen C, Zhang C, et al. Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors. Ann Med. 2025;57(1):2531255.","journal-title":"Ann Med"},{"issue":"1","key":"4330_CR234","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","volume":"7","author":"R Gonzalez-Exposito","year":"2019","unstructured":"Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody Cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019;7(1):101.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4330_CR235","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0b013e31819b7c70","volume":"32","author":"R Lutterbuese","year":"2009","unstructured":"Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, et al. Potent control of tumor growth by CEA\/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32(4):341\u201352.","journal-title":"J Immunother"},{"key":"4330_CR236","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02251-x","author":"A Ono","year":"2025","unstructured":"Ono A, Hayes CN, Miura R, Kawaoka T, Tsuge M, Oka S. Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma. J Gastroenterol. 2025. https:\/\/doi.org\/10.1007\/s00535-025-02251-x.","journal-title":"J Gastroenterol"},{"key":"4330_CR237","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163291","author":"X Lu","year":"2023","unstructured":"Lu X, Deng S, Xu J, Green BL, Zhang H, Cui G, et al. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models. J Clin Investig. 2023. https:\/\/doi.org\/10.1172\/JCI163291.","journal-title":"J Clin Investig"},{"issue":"24","key":"4330_CR238","doi-asserted-by":"publisher","first-page":"16988","DOI":"10.18632\/oncotarget.24769","volume":"9","author":"M Afshar","year":"2018","unstructured":"Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with Sorafenib: a large UK cohort. Oncotarget. 2018;9(24):16988\u201395.","journal-title":"Oncotarget"},{"issue":"12","key":"4330_CR239","first-page":"4547","volume":"10","author":"WF Hsu","year":"2020","unstructured":"Hsu WF, Chuang PH, Chen CK, Wang HW, Tsai MH, Su WP, et al. Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. Am J Cancer Res. 2020;10(12):4547\u201360.","journal-title":"Am J Cancer Res"},{"issue":"11","key":"4330_CR240","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1111\/liv.14210","volume":"39","author":"YY Shao","year":"2019","unstructured":"Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019;39(11):2184\u20139.","journal-title":"Liver Int"},{"issue":"8","key":"4330_CR241","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00432-021-03727-y","volume":"148","author":"HI Kim","year":"2022","unstructured":"Kim HI, Lim J, Shim JH. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2022;148(8):2069\u201377.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4330_CR242","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s12072-022-10358-z","volume":"16","author":"T Hatanaka","year":"2022","unstructured":"Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hep Intl. 2022;16(5):1150\u201360.","journal-title":"Hep Intl"},{"issue":"1","key":"4330_CR243","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JS9.0000000000001860","volume":"111","author":"Z Yang","year":"2025","unstructured":"Yang Z, Fu Y, Wang Q, Pan Y, Wang J, Chen J, et al. Dynamic changes of serum alpha-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma. Int J Surg. 2025;111(1):751\u201360.","journal-title":"Int J Surg"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04330-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04330-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04330-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:59Z","timestamp":1790164919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04330-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":243,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04330-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors report no relevant conflicts of interest for this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have given consent to publish.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}